Albumin mRNA—A Hepatocyte-Specific Indicator

Case Background

Patient: Male, 68 years old.

Present Illness History: The patient was admitted to the hospital 20 days after experiencing discomfort in the upper abdomen without any obvious cause. There were no symptoms of acid reflux or heartburn, nausea, or vomiting, and no specific treatment was undertaken. Within 3 days, the symptoms gradually worsened, leading to a hospital visit. Since the onset of the illness, the patient has been conscious and alert, presenting a chronic disease appearance, pallor from anemia, discomfort in the upper and middle abdomen, poor appetite, fair nighttime sleep, normal bowel movements, and no significant weight loss.

Clinical Diagnosis

Liver space-occupying lesion, malignant tumor?

Hepatitis B virus infection

Hypertension, Stage 2 (high risk)

HE?Stain

IHC Stain

IHC: ?CK7 (negative), CK19 (negative), Hepa (negative), Arg-1 (negative), Gpc-3 (negative), , , CDX2 (negative), SATB2 (negative), TTF1 (negative)

Pathological Diagnosis (Liver biopsy) Hepatocellular carcinoma, poorly differentiated.

Highlight

Hepatocyte Antigen (HepPar-1) and Arginase-1 (Arg-1) are commonly used biomarkers in the pathological diagnosis of hepatocellular carcinoma (HCC), but both have low positive rates in poorly differentiated HCC, making the differential diagnosis of poorly differentiated HCC challenging.

Albumin mRNA—A Hepatocyte-Specific Indicator: Numerous studies both domestically and internationally have shown that using in situ hybridization to detect albumin mRNA can effectively identify hepatocellular carcinoma and also has a good detection effect for intrahepatic cholangiocarcinoma. It can assist in accurately identifying cancer cells originating from hepatocytes and in the differential diagnosis with metastatic tumors originating from outside the liver.

copyright@Celnovte biotechnology Co., Ltd